Quality Chemical Industries Limited (Qcil) Launches Hydroxyurea Treatment to Improve Care for Sickle Cell Disease Patients

Kampala, Uganda- 20^th May 2026 – Quality Chemical Industries Limited (Qcil), Uganda’s leading pharmaceutical manufacturer, has today announced the launch of Hydroxyurea, a life-saving medication used in the management of Sickle Cell Disease (SCD). This initiative marks a significant milestone in improving access to affordable and effective treatment for thousands of Ugandans affected by the condition.

The launch comes at a time when sickle cell disease remains a major public health challenge in Uganda, with an estimated 20,000 babies born with the condition each year. Hydroxyurea is clinically proven to reduce painful crises, decrease hospital admissions, and improve the overall quality of life for patients living with SCD.

Speaking at the launch, Ajay Kumar Pal, the Chief Executive Officer at Quality Chemical Industries Limited, emphasised the company’s commitment to addressing critical healthcare needs in Uganda and the region. 

^{Ajay Kumar Pal, the Chief Executive Officer at Quality Chemical Industries Limited speaking at the Launch}

“At Qcil, we are dedicated to enhancing access to essential medicines for diseases that cause the greatest public health burden to our continent. The introduction of locally manufactured Hydroxyurea represents a major step forward in ensuring that warriors fighting Sickle Cell Disease receive reliable, affordable, and high-quality treatment,” Ajay Kumar, Qcil CEO, added.

The local production of Hydroxyurea is expected to lower treatment costs, improve availability, and reduce dependence on imported medicines. Qcil continues to collaborate with the Ministry of Health, healthcare providers, and development partners to strengthen the response to non-communicable diseases, including Sickle Cell Disease.

The Permanent Secretary at the Ministry of Health, Dr Diana Atwine, was the chief guest at the launch. She commended Qcil for the timely development, noting that increased access to Hydroxyurea will lead to better disease management outcomes, fewer complications, and a reduced strain on healthcare facilities. 

^{The Permanent Secretary at the Ministry of Health, Dr Diana Atwine launching the Hydroxyurea Manufacturing Facility at Qcil, Luzira}

“This milestone aligns with Uganda’s broader strategy to manage Sickle Cell Disease. Through joint efforts, we want to embed the fight against Sickle Cell Disease in our primary health care system and take it across all fronts, including among religious leaders who wed the carrier couples.” Dr Atwine noted.

Sickle Cell Disease becomes yet another of the growing number of therapeutic areas for which medicine Qcil manufactures, after 20 years of producing affordable, high-quality HIV and malaria medications.